Literature DB >> 16230269

Canine nonischemic left ventricular dysfunction: a model of chronic human cardiomyopathy.

Yoshinori Nishijima1, David S Feldman, John D Bonagura, Yunusemre Ozkanlar, Paula J Jenkins, Veronique A Lacombe, William T Abraham, Robert L Hamlin, Cynthia A Carnes.   

Abstract

BACKGROUND: The mechanisms of cardiac remodeling during chronic heart failure remain poorly defined. We sought to advance a chronic canine model of nonischemic cardiomyopathy. METHODS AND
RESULTS: Male dogs (n = 6) received decremental right ventricular apical tachypacing (12 months) to achieve and maintain stable left ventricular (LV) dysfunction. After 10 months of tachypacing, 120 beats/min was sufficient to maintain stable LV dysfunction. Electrocardiography, echocardiography, and tissue Doppler imaging were done to evaluate electrophysiology, LV dimensions and function, and dyssynchrony during normal sinus rhythm. The 6-minute walk test was used to evaluate functional capacity. We observed increases in both QRS duration (P < .0001) and QRS amplitude (P < .0001). LV fractional shortening was reduced from a baseline of 38.0 +/- 1.4% to 11.2 +/- 1.4% (P < .0001). LV end-diastolic dimension increased from 3.8 +/- 0.1 cm at baseline to 5.3 +/- 0.3 cm (P < .0001); LV end-systolic dimension increased from 2.3 +/- 0.1 cm to 4.7 +/- 0.2 cm (P < .0001). LV mass increased from 85.9 +/- 3.5 g at baseline to 179 +/- 13.7 g (P < .0001). There was evidence of LV dyssynchrony (P < .04) during both normal sinus rhythm and right ventricular tachypacing, compared with control dogs. The distance a dog walked in 6 minutes was significantly less at 12 months compared with normal controls (540 +/- 32 m versus 277 +/- 64 m, P < .008).
CONCLUSION: This nonischemic model of canine cardiomyopathy reproduces many aspects of chronic human heart failure including reduced fractional shortening, dilated ventricular dimensions, increased LV mass, decreased functional capacity, and dyssynchrony.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16230269     DOI: 10.1016/j.cardfail.2005.05.006

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  15 in total

1.  Differential regulation of EHD3 in human and mammalian heart failure.

Authors:  Hjalti Gudmundsson; Jerry Curran; Farshid Kashef; Jedidiah S Snyder; Sakima A Smith; Pedro Vargas-Pinto; Ingrid M Bonilla; Robert M Weiss; Mark E Anderson; Philip Binkley; Robert B Felder; Cynthia A Carnes; Hamid Band; Thomas J Hund; Peter J Mohler
Journal:  J Mol Cell Cardiol       Date:  2012-03-03       Impact factor: 5.000

2.  Enhanced ryanodine receptor-mediated calcium leak determines reduced sarcoplasmic reticulum calcium content in chronic canine heart failure.

Authors:  Andriy Belevych; Zuzana Kubalova; Dmitry Terentyev; Robert L Hamlin; Cynthia A Carnes; Sandor Györke
Journal:  Biophys J       Date:  2007-09-07       Impact factor: 4.033

3.  The role of spatial organization of Ca2+ release sites in the generation of arrhythmogenic diastolic Ca2+ release in myocytes from failing hearts.

Authors:  Andriy E Belevych; Hsiang-Ting Ho; Ingrid M Bonilla; Radmila Terentyeva; Karsten E Schober; Dmitry Terentyev; Cynthia A Carnes; Sándor Györke
Journal:  Basic Res Cardiol       Date:  2017-06-13       Impact factor: 17.165

4.  Chronic heart failure and the substrate for atrial fibrillation.

Authors:  Arun Sridhar; Yoshinori Nishijima; Dmitry Terentyev; Mahmood Khan; Radmila Terentyeva; Robert L Hamlin; Tomohiro Nakayama; Sandor Gyorke; Arturo J Cardounel; Cynthia A Carnes
Journal:  Cardiovasc Res       Date:  2009-06-30       Impact factor: 10.787

5.  Dysfunction of the β2-spectrin-based pathway in human heart failure.

Authors:  Sakima A Smith; Langston D Hughes; Crystal F Kline; Amber N Kempton; Lisa E Dorn; Jerry Curran; Michael Makara; Tyler R Webb; Patrick Wright; Niels Voigt; Philip F Binkley; Paul M L Janssen; Ahmet Kilic; Cynthia A Carnes; Dobromir Dobrev; Matthew N Rasband; Thomas J Hund; Peter J Mohler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-04-22       Impact factor: 4.733

6.  Molecular mechanisms underlying cardiac protein phosphatase 2A regulation in heart.

Authors:  Sean T DeGrande; Sean C Little; Derek J Nixon; Patrick Wright; Jedidiah Snyder; Wen Dun; Nathaniel Murphy; Ahmet Kilic; Robert Higgins; Philip F Binkley; Penelope A Boyden; Cynthia A Carnes; Mark E Anderson; Thomas J Hund; Peter J Mohler
Journal:  J Biol Chem       Date:  2012-11-30       Impact factor: 5.157

7.  Tetrahydrobiopterin depletion and NOS2 uncoupling contribute to heart failure-induced alterations in atrial electrophysiology.

Authors:  Yoshinori Nishijima; Arun Sridhar; Ingrid Bonilla; Murugesan Velayutham; Mahmood Khan; Radmila Terentyeva; Chun Li; Periannan Kuppusamy; Terry S Elton; Dmitry Terentyev; Sandor Györke; Jay L Zweier; Arturo J Cardounel; Cynthia A Carnes
Journal:  Cardiovasc Res       Date:  2011-04-01       Impact factor: 10.787

8.  Heart failure duration progressively modulates the arrhythmia substrate through structural and electrical remodeling.

Authors:  Victor P Long; Ingrid M Bonilla; Pedro Vargas-Pinto; Yoshinori Nishijima; Arun Sridhar; Chun Li; Kent Mowrey; Patrick Wright; Murugesan Velayutham; Sanjay Kumar; Nam Y Lee; Jay L Zweier; Peter J Mohler; Sandor Györke; Cynthia A Carnes
Journal:  Life Sci       Date:  2015-01-14       Impact factor: 5.037

9.  Chronic cardiac resynchronization therapy and reverse ventricular remodeling in a model of nonischemic cardiomyopathy.

Authors:  Yoshinori Nishijima; Arun Sridhar; Serge Viatchenko-Karpinski; Courtney Shaw; John D Bonagura; William T Abraham; Mandar S Joshi; John Anthony Bauer; Robert L Hamlin; Sandor Györke; David S Feldman; Cynthia A Carnes
Journal:  Life Sci       Date:  2007-08-30       Impact factor: 5.037

10.  Differential expression of sarcolipin protein during muscle development and cardiac pathophysiology.

Authors:  Gopal J Babu; Poornima Bhupathy; Cynthia A Carnes; George E Billman; Muthu Periasamy
Journal:  J Mol Cell Cardiol       Date:  2007-05-18       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.